Improving executive function in young people with 22q11.2 deletion syndrome using brain stimulation
Using Transcranial Alternating Current Stimulation With Starstim Home Device to Improve Executive Function in Youths With 22q11.2 Deletion Syndrome: A Randomized Double-blind Sham-controlled Study
This study is testing if a type of brain stimulation can help improve memory and thinking skills in children and young adults with 22q11.2 deletion syndrome.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 40 (estimated) |
| Ages | 14 Years to 25 Years |
| Sex | All |
| Sponsor | University of Geneva, Switzerland Academic / other |
| Locations | 1 site (Geneva, Canton of Geneva) |
| Trial ID | NCT05664412 on ClinicalTrials.gov |
What this trial studies
This project investigates the effects of transcranial alternating current stimulation (tACS) on cognitive function in children, adolescents, and young adults with 22q11.2 deletion syndrome. The study aims to enhance visual working memory performance through a non-invasive brain stimulation protocol tailored to individual participants. By targeting cognitive deficits early, the research seeks to mitigate the risk of developing psychotic symptoms later in life. Participants will receive at-home tACS treatments using the Starstim-Home device, allowing for personalized intervention based on their specific needs.
Who should consider this trial
Good fit: Ideal candidates are individuals aged 14 to 25 with a confirmed genetic diagnosis of 22q11.2 deletion syndrome.
Not a fit: Patients with epilepsy, deep brain stimulation electrodes, traumatic brain injury, or facial metal implants may not benefit from this study.
Why it matters
Potential benefit: If successful, this intervention could improve cognitive function and potentially delay or prevent the onset of psychotic symptoms in individuals with 22q11.2 deletion syndrome.
How similar studies have performed: While the approach of using tACS for cognitive enhancement is relatively novel, similar studies have shown promise in improving cognitive functions in other populations.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Confirmed genetic diagnosis of 22q11DS * Age between 14 and 25 years old * Willingness to participate * Informed Consent signed by the subject and/or the caregiver(s) Exclusion Criteria: * Epilepsy * Deep brain stimulation electrodes * Traumatic brain injury * Facial metal implants
Where this trial is running
Geneva, Canton of Geneva
- University of Geneva — Geneva, Canton of Geneva, Switzerland (Recruiting)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.